High-resolution structures explain the mechanism of human PNPase and provide insights into mutations causing hereditary ...
An investigational GLP-1 pill from Structure Therapeutics led to substantial weight loss, but patients also had high rates of ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related ...
New simulations of Milky Way-like galaxies reveal that the strange split between two chemically distinct groups of stars may ...
Note: The verification e-mail to complete your account registration should arrive immediately. However, in some cases it takes longer. Don't forget to check your spam folder.
Discover why Structure Therapeutics Inc. is rated Strong Buy after positive Aleniglipron phase 2b obesity data. Click for ...
The multidrug-resistant pathogen Acinetobacter baumannii (A. baumannii) is a global health concern. Its surface capsular ...
Structure's aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech's stock up nearly 103% as ...
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today ...
Cholera is a deadly bacterial disease that kills about 95,000 people every year. Vibrio cholerae bacteria infect cells in the ...
Interesting Engineering on MSN
Scientists engineer crystal with rare magnetic swirls that could reshape data storage
FSU scientists create a new crystal with swirling magnetic textures, opening paths to denser storage and future quantum ...
Clues about how galaxies like our Milky Way form and evolve and why their stars show surprising chemical patterns have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback